Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis
A Multicenter Trial of Adjuvant Interferon Alfa-2b for Melanoma Patients With Early Lymph Node Metastasis Detected by Lymphatic Mapping and Sentinel Lymph Node Biopsy
Sponsor: National Cancer Institute (NCI)
Listed as NCT00004196, this PHASE3 trial focuses on Melanoma (Skin) and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 1999, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Oct 1999
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- University of Alabama at Birmingham
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Birmingham, United States
- • Buffalo, United States
- • Louisville, United States
- • New Brunswick, United States